Research

At Logan Health, research is more than discovery; it’s about bringing new hope, new options, and better outcomes directly to our patients. We are continually exploring innovative ways to prevent, detect, and treat disease, giving you access to tomorrow’s medicine today.

By participating in research, patients become partners in advancing care, not just for themselves, but for their families, neighbors, and future generations.

Research studies evaluate new approaches to health care.

What Are Clinical Trials?

Clinical trials are research studies that evaluate new approaches to health care. These may include new medications, medical devices, or new uses for existing treatments.

Each study follows a detailed plan, called a protocol, that outlines how the research will be conducted and who may participate. This ensures that every trial meets the highest standards for safety, accuracy, and consistency.

Before enrolling, you’ll have the opportunity to ask questions and fully understand what your participation involves, so you can make a confident, informed decision.

For many patients, clinical trials provide not only options but renewed optimism.

Why Consider Participating?

Taking part in a clinical trial can offer meaningful benefits, both personal and far-reaching:

Access to advanced care: Participants receive high-quality treatment and close monitoring throughout the study. If you are not receiving the new treatment, you may still receive the current standard of care.
Early access to promising therapies: You may be among the first to benefit from new treatments before they are widely available.
A more personalized experience: Clinical trials often include additional attention, follow-ups, and testing to closely track your health.
Helping others: Your participation contributes to medical breakthroughs that can improve care for countless others in the future.

For many patients, clinical trials provide not only options, but renewed optimism.

You will always be informed and cared for during this process.

Understanding the Risks

It’s important to weigh both benefits and risks when considering a clinical trial:

New treatments may not always be more effective than current standard therapies.
Unexpected side effects can occur, and some may be more significant than those of existing treatments.
Not every treatment works the same for every person; even well-established therapies can vary in effectiveness.
Participation may require additional time, appointments, or travel.

Our care teams will walk you through these considerations so you can decide what’s right for you.

You are never alone in this process.

Your Safety Comes First

Your well-being is our highest priority. Every clinical trial at Logan Health is guided by strict safety standards:

Participation is completely voluntary, and you may withdraw at any time.
Studies follow federal regulations designed to protect your health and rights.
Independent Institutional Review Boards (IRBs) oversee each study to ensure it is ethical and safe.

You are never alone in the process. Our research teams are here to support you every step of the way.

Advancing Care Together

Clinical research is how medicine moves forward. At Logan Health, it also represents a powerful partnership between patients and providers, working together to improve lives.

Whether you’re exploring new treatment options or looking for ways to make a difference, participating in a clinical trial may open the door to both.

Patient Resources

“I am 66 years old and have had psoriatic arthritis for 35 years. When the opportunity came up for participating in a trial, I gladly accepted. I have been participating for a little over a year and the experience has been wonderful. Not only is the staff highly professional, they have the ability to be professional and personable at the same time. The trial process is very detailed and done in a professional manner. I enjoy myself every time I go because of the staff; they are fantastic. Not only is this drug helping, it’s fun at the same time. Hopefully, this trial will benefit many others.”

Joanne Wiles

“I came into the trial experience as a newcomer. I was excited to try new medication but I was apprehensive about the unknown. I think of myself as a positive person, and I always try to see the good in everything and everyone. Boy, was I in for a pleasant surprise! I felt I could ask or tell them anything, and I had their undivided attention. I couldn’t have had a more professional team! I am sorry the trial is over because I always looked forward to seeing them. They couldn’t have done a better job.”

Donald Timm

“I met with Jaime Wyatt (clinical research coordinator) for screening to see if I was a candidate for a clinical study. I was accepted and completed that five-year study. I started with 15 painful and swollen joints and psoriasis over 40% of my body and ended with only three painful joints with my skin clear. A year and a half later, I learned about another study with the same team. I was happy to be considered and am currently in that study.”

Christie Hanson

“The process is well-organized and thorough; communication is clear, and they have a great system. I always know what to expect at each visit. I appreciate that I can communicate any questions or concerns at any time and get the information that I need. I still have a couple of painful joints, but am very satisfied with the treatment and results of these studies. These studies and this team have been a great help to my quality of life. I am so appreciative and would recommend this team to others.”

Christie Hanson continued

“Because of my clinical study group team, I’ve always felt that I have caring people in my corner. The coordinator, Jaime, was an angel to deal with and always kept me optimistic about reality, and the doctor and his knowledge helped to calm my nerves when I would flare up. These study groups are way more than just appointments and medicine. I wouldn’t be who I am today without being part of this experience.”

Michael Smith

Open to Enrollment Studies

Hematology & Oncology (Cancer)

MONTANA CANCER CONSORTIUM (NCORP)TRIALS
The Montana Cancer Consortium is an NCI Community Oncology Research Program (NCORP) that gives patients at Logan Health access to more than 100 clinical trials for various disease sites, including brain, breast, lung, gastrointestinal, genitourinary, gynecological, lymphomas, melanoma, multiple myeloma, and neuroendocrine diseases. These trials are sponsored by cooperative groups in the U.S. (i.e., ALLIANCE, ECOG-ACRIN, NRG, SWOG) and the National Cancer Institute (NCI). This includes treatment trials, cancer prevention trials, and cancer care delivery research (CCDR). For more information on the open trials available, visit www.mtcancer.org

Site Principal Investigator, Elise Anderes, MD
Contact: Deptresearch@logan.org – (406) 752-7636

Exact Sciences – 2021-05
Specimen Collection Study to evaluate biomarkers in subjects with cancer.

Site Principle Investigator, Elise Anderes, MD
Contact: Deptresearch@logan.org – (406) 752-7636

Daiichi Sanko – DS8201-793
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

Site Principle Investigator, Elise Anderes, MD
Contact: Deptresearch@logan.org – (406) 752-7636

Cardiology

AMG 133 20230227
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living with Heart Failure with Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

Principal Investigator: Eve Gillespie, MD, PhD
Contact: Deptresearch@logan.org – (406) 752-7636

COMING SOON

R7508-CVA-24114
A Phase 3, Randomized, Multicenter, Double-blind study to Assess Stroke and Systemic Embolism Prevention with REGN7508, a Monoclonal Antibody Against FXI, versus Apixaban in Participants with Atrial Fibrillation (ROXI-EVEREST)

Principal Investigator: Eve Gillespie, MD, PhD
Contact: Deptresearch@logan.org – (406) 752-7636

R9933-CVA-2495
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO ASSESS STROKE AND SYSTEMIC EMBOLISM PREVENTION WITH REGN7508 AND REGN9933, MONOCLONAL ANTIBODIES AGAINST FACTOR XI, VERSUS PLACEBO IN PARTICIPANTS WITH ATRIAL FIBRILLATION FOR WHOM ORAL ANTICOAGULATION IS UNSUITABLE (ROXI-INCLINE)

Principal Investigator: Eve Gillespie, MD, PhD
Contact: Deptresearch@logan.org – (406) 752-7636

Endocrinology

Contact: DEPTresearch@logan.org – (406) 752-7636 for ongoing or upcoming clinical trials

Rheumatology

ELI LILLY – I1F-MC-RHDE
A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide after Initiation of Ixekizumab in Adult Participants with Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice